Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139678 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | December 2020 | July 2021 | Allow | 7 | 1 | 1 | No | No |
| 16978903 | SYSTEMS AND METHODS FOR ASSESSING COLORECTAL CANCER MOLECULAR SUBTYPE AND RISK OF RECURRENCE AND FOR DETERMINING AND ADMINISTERING TREATMENT PROTOCOLS BASED THEREON | December 2020 | August 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 17103812 | VECTORS & METHODS | November 2020 | August 2022 | Abandon | 21 | 2 | 1 | No | No |
| 17060534 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | October 2020 | October 2021 | Allow | 12 | 3 | 1 | Yes | No |
| 16938136 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | July 2020 | December 2020 | Allow | 5 | 1 | 1 | No | No |
| 16933540 | HTP PLATFORM FOR THE GENETIC ENGINEERING OF CHINESE HAMSTER OVARY CELLS | July 2020 | February 2021 | Allow | 6 | 1 | 1 | Yes | No |
| 16769558 | Method for characterizing biological part based on dual-fluorescent reporter gene system and biological part library constructed thereon | June 2020 | October 2021 | Allow | 17 | 1 | 1 | No | No |
| 16757003 | DELTA-LIKE LIGAND 1 FOR DIAGNOSING SEVERE INFECTIONS | April 2020 | August 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16849441 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES | April 2020 | June 2021 | Allow | 14 | 0 | 1 | Yes | No |
| 16849455 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES | April 2020 | June 2021 | Allow | 14 | 0 | 1 | Yes | No |
| 16846133 | DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS | April 2020 | April 2024 | Allow | 48 | 1 | 0 | No | No |
| 16842719 | INTEGRATION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC CELLS WITH A TRANSPOSASE FROM ORYZIAS | April 2020 | April 2021 | Allow | 12 | 1 | 1 | No | No |
| 16831675 | ENDOPHYTE COMPOSITIONS AND THE METHODS FOR IMPROVEMENT OF PLANT TRAITS | March 2020 | March 2024 | Allow | 48 | 1 | 0 | No | No |
| 16825710 | POOLED GENOME EDITING IN MICROBES | March 2020 | February 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16812138 | RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS | March 2020 | November 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16680104 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | November 2019 | July 2020 | Allow | 8 | 0 | 1 | Yes | No |
| 16541354 | APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING | August 2019 | June 2021 | Allow | 22 | 2 | 1 | Yes | Yes |
| 16460455 | LIQUID BASED SELECTION AND CELL ISOLATION | July 2019 | April 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16417523 | BIOLOGICAL DETECTION METHOD FOR DIOXINS IN SERUM, AND DIAGNOSTIC USE THEREFOR IN METABOLIC SYNDROME AND RELATED CONDITIONS | May 2019 | February 2020 | Allow | 9 | 1 | 0 | No | No |
| 16347723 | A TWO-PART DEVICE FOR T-CELL RECEPTOR SYNTHESIS AND STABLE GENOMIC INTEGRATION TO TCR-PRESENTING CELLS | May 2019 | July 2021 | Allow | 26 | 1 | 1 | Yes | No |
| 16369565 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | March 2019 | April 2024 | Allow | 60 | 1 | 0 | No | No |
| 16362897 | RECOMBINANT MICROORGANISMS CAPABLE OF CARBON FIXATION | March 2019 | April 2024 | Allow | 60 | 1 | 0 | No | No |
| 16335515 | HIGH MOBILITY GROUP BOX I MUTANT | March 2019 | April 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16353248 | Algorithms for Disease Diagnostics | March 2019 | February 2020 | Allow | 11 | 1 | 1 | Yes | No |
| 16256483 | METHOD FOR PREDICTING THE RESPONSE TO CHEMOTHERAPY IN A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING RECURRENT BREAST CANCER | January 2019 | September 2022 | Abandon | 43 | 1 | 0 | No | No |
| 16229853 | ENGINEERED MICROBES FOR RARE EARTH ELEMENT ADSORPTION | December 2018 | September 2021 | Allow | 33 | 2 | 1 | Yes | No |
| 16219553 | DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS | December 2018 | March 2019 | Allow | 3 | 1 | 0 | No | No |
| 16092414 | A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION | October 2018 | May 2022 | Abandon | 43 | 0 | 1 | No | No |
| 16153052 | METHODS FOR SCREENING BACTERIA, ARCHAEA, ALGAE, AND YEAST USING CRISPR NUCLEIC ACIDS | October 2018 | October 2021 | Allow | 36 | 5 | 0 | Yes | No |
| 16091874 | COMPOSITIONS FOR ERADICATING FLAVIVIRUS INFECTIONS IN SUBJECTS | October 2018 | April 2022 | Abandon | 42 | 0 | 1 | No | No |
| 16079740 | SYNTHETIC TRANSLATION-SENSING RIBOSWITCHES AND USES THEREOF | August 2018 | September 2019 | Allow | 13 | 1 | 1 | No | No |
| 16073343 | KIT FOR CONSTRUCTING TRANSPOSON AND USE THEREOF | July 2018 | January 2022 | Allow | 41 | 1 | 1 | Yes | No |
| 16038832 | DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS | July 2018 | December 2018 | Allow | 5 | 1 | 0 | Yes | No |
| 16027478 | METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION | July 2018 | August 2022 | Abandon | 49 | 2 | 1 | No | No |
| 15563345 | NOVEL GENE REGULATING VIRULENCE OF CRYPTOCOCCUS NEOFORMANS, AND USE THEREOF | June 2018 | August 2021 | Abandon | 46 | 0 | 1 | No | No |
| 16000607 | BIOMARKERS OF ENDOGENOUS BIOLOGICAL TIME | June 2018 | January 2022 | Allow | 43 | 1 | 1 | Yes | No |
| 15989400 | Method for Producing Fibroin-Like Protein | May 2018 | May 2021 | Allow | 36 | 1 | 0 | Yes | No |
| 15977788 | Host Cells and Systems for Membrane Protein Expression | May 2018 | December 2021 | Allow | 43 | 1 | 1 | No | No |
| 15968517 | METHOD TO ENHANCE IMMUNOGENICITY OF LIVE TYPHOID VACCINES AND CARRIERS | May 2018 | October 2021 | Allow | 41 | 2 | 1 | No | No |
| 15746621 | A High-secretion Heat-resistant Yeast Genetically Engineered Strain and Application Thereof | April 2018 | October 2019 | Allow | 21 | 1 | 1 | No | No |
| 15957672 | Transcriptional system and uses thereof for single cell detection | April 2018 | September 2021 | Abandon | 41 | 1 | 1 | No | No |
| 15953974 | MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY | April 2018 | March 2021 | Abandon | 35 | 0 | 1 | No | No |
| 15949581 | SPECIFIC AND HIGH AFFINITY BINDING PROTEINS COMPRISING MODIFIED SH3 DOMAINS OF FYN KINASE | April 2018 | January 2021 | Allow | 33 | 1 | 0 | No | No |
| 15942681 | GLUCOSE SENSORS AND METHODS OF USE THEREOF | April 2018 | August 2019 | Allow | 17 | 2 | 1 | No | No |
| 15765043 | METHOD FOR EXTRACTING 2',3'-CYCLIC NUCLEOSIDE MONOPHOSPHATES | March 2018 | October 2020 | Allow | 30 | 1 | 0 | Yes | No |
| 15940282 | RECOMBINANT PROTEIN EXPRESSION USING A HYBRID CHEF1 PROMOTER | March 2018 | March 2021 | Abandon | 36 | 1 | 0 | No | No |
| 15935761 | LABORATORY CENTRAL CONTROL UNIT METHOD AND SYSTEM | March 2018 | February 2022 | Allow | 46 | 2 | 1 | No | No |
| 15762730 | METHODS AND COMPOSITIONS FOR SEQUENCE SPECIFIC ANTIMICROBIALS | March 2018 | December 2021 | Allow | 45 | 3 | 1 | Yes | No |
| 15762551 | NOVEL EPISOMAL PLASMID VECTORS | March 2018 | June 2021 | Allow | 39 | 1 | 1 | No | No |
| 15761598 | OPTOGENETIC SYSTEM BASED ON BACTERIAL PHYTOCHROME CONTROLLABLE WITH NEAR INFRA-RED LIGHT | March 2018 | February 2021 | Allow | 35 | 1 | 1 | Yes | No |
| 15925301 | COMPOSITIONS AND METHODS FOR THE BIOSYNTHESIS OF 1,4-BUTANEDIOL AND ITS PRECURSORS | March 2018 | April 2021 | Abandon | 37 | 1 | 1 | No | No |
| 15922763 | GENES INVOLVED IN ASTAXANTHIN BIOSYNTHESIS | March 2018 | May 2021 | Allow | 38 | 1 | 1 | Yes | No |
| 15916274 | NOVEL CRISPR RNA TARGETING ENZYMES AND SYSTEMS AND USES THEREOF | March 2018 | July 2021 | Allow | 40 | 2 | 1 | No | No |
| 15916271 | NOVEL CRISPR RNA TARGETING ENZYMES AND SYSTEMS AND USES THEREOF | March 2018 | June 2019 | Allow | 15 | 1 | 1 | Yes | No |
| 15914602 | Boranephosphonate Detection Probes and Methods For Producing and Using the Same | March 2018 | July 2021 | Abandon | 40 | 2 | 1 | No | No |
| 15757325 | YEAST STRAINS FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS AT HIGH TEMPERATURES | March 2018 | January 2022 | Allow | 46 | 2 | 1 | Yes | No |
| 15904069 | SCAFFOLD PROTEINS DERIVED FROM PLANT CYSTATINS | February 2018 | August 2020 | Allow | 30 | 1 | 1 | No | No |
| 15754524 | YEAST ALLELES INVOLVED IN TOLERANCE TO HIGH ALCOHOL LEVELS | February 2018 | June 2021 | Allow | 40 | 1 | 1 | No | No |
| 15754589 | NUCLEASE WITH ENHANCED EFFICIENCY OF GENOME EDITING | February 2018 | January 2022 | Allow | 47 | 3 | 1 | Yes | No |
| 15899051 | Novel Cell Line Screening Method | February 2018 | July 2020 | Allow | 29 | 1 | 1 | Yes | No |
| 15898513 | METHODS AND SYSTEMS FOR ANALYSIS OF ORGAN TRANSPLANTATION | February 2018 | July 2020 | Allow | 29 | 1 | 1 | No | No |
| 15892330 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | February 2018 | June 2020 | Allow | 28 | 1 | 1 | Yes | No |
| 15892356 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN | February 2018 | February 2020 | Allow | 24 | 1 | 1 | No | No |
| 15888734 | CELL CO-CULTURE SYSTEMS AND USES THEREOF | February 2018 | November 2020 | Abandon | 33 | 1 | 1 | No | No |
| 15750334 | Promoter Variants | February 2018 | March 2020 | Allow | 25 | 1 | 1 | Yes | No |
| 15749544 | GDF-15 as a Haematological Toxicity Biomarker | February 2018 | October 2020 | Allow | 33 | 1 | 1 | Yes | No |
| 15884543 | COMPOSITION FOR SOLUBILIZING TARGET PROTEIN AND USE THEREOF | January 2018 | May 2020 | Allow | 28 | 1 | 1 | No | No |
| 15875871 | MOLECULAR SUBTYPING, PROGNOSIS, AND TREATMENT OF BLADDER CANCER | January 2018 | August 2021 | Allow | 43 | 2 | 1 | No | No |
| 15745030 | BASE SEQUENCE FOR PROTEIN EXPRESSION AND METHOD FOR PRODUCING PROTEIN USING SAME | January 2018 | February 2020 | Allow | 25 | 1 | 1 | No | No |
| 15869683 | METHOD FOR PREDICTING THE OUTCOME OF COLON CANCER BY ANALYSING MIRNA EXPRESSION | January 2018 | November 2019 | Abandon | 22 | 0 | 1 | No | No |
| 15868136 | METHOD FOR RECONSTRUCTING ASPERGILLUS NIGER TO INCREASE CITRATE PRODUCTION | January 2018 | December 2019 | Allow | 23 | 1 | 1 | No | No |
| 15867836 | Method for increasing citric acid production by Aspergillus niger fermentation | January 2018 | January 2020 | Allow | 24 | 1 | 1 | No | No |
| 15742525 | PHARMACEUTICAL COMPOSITION FOR INHIBITING RESISTANCE AGAINST ANTICANCER DRUGS OF PATIENT SUFFERING FROM OVARIAN CANCER COMPRISING NAG-1 INHIBITOR AS ACTIVE INGREDIENT | January 2018 | December 2021 | Allow | 47 | 4 | 1 | Yes | No |
| 15738918 | MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS | December 2017 | December 2020 | Allow | 36 | 2 | 1 | Yes | Yes |
| 15851377 | METHODS FOR PROCESSING OR ANALYZING SAMPLE OF THYROID TISSUE | December 2017 | September 2018 | Allow | 9 | 1 | 1 | Yes | No |
| 15738555 | MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS | December 2017 | May 2020 | Allow | 29 | 2 | 1 | No | No |
| 15846279 | HIGH EFFICIENCY GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS BY A MULTIPLE TRANSFECTION PROCEDURE OF MAR SEQUENCES | December 2017 | January 2020 | Allow | 25 | 1 | 1 | No | No |
| 15737516 | RNA-GUIDED TRANSCRIPTIONAL REGULATION AND METHODS OF USING THE SAME FOR THE TREATMENT OF BACK PAIN | December 2017 | November 2020 | Allow | 35 | 2 | 1 | No | No |
| 15844014 | METHODS OF CELL RENEWAL | December 2017 | October 2021 | Allow | 46 | 3 | 1 | No | No |
| 15840958 | NONLINEAR OPTICAL DETECTION OF MOLECULES COMPRISING AN UNNATURAL AMINO ACID POSSESSING A HYPERPOLARIZABILITY | December 2017 | August 2019 | Abandon | 20 | 0 | 1 | No | No |
| 15579841 | AMINO ACID-MODIFIED NUCLEIC ACID AND UTILIZATION THEREOF | December 2017 | May 2020 | Allow | 29 | 2 | 1 | Yes | No |
| 15829844 | ENDOPHYTE COMPOSITIONS AND THE METHODS FOR IMPROVEMENT OF PLANT TRAITS | December 2017 | December 2019 | Allow | 25 | 1 | 1 | Yes | No |
| 15827044 | METHODS FOR DIAGNOSING AUTISM SPECTRUM DISORDERS | November 2017 | January 2020 | Allow | 25 | 1 | 1 | No | No |
| 15826671 | METHODS AND MATERIALS FOR CLONING FUNCTIONAL T CELL RECEPTORS FROM SINGLE T CELLS | November 2017 | November 2020 | Allow | 35 | 3 | 1 | Yes | No |
| 15811841 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION | November 2017 | January 2020 | Allow | 26 | 1 | 1 | No | No |
| 15799699 | METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER | October 2017 | January 2019 | Allow | 14 | 1 | 0 | No | No |
| 15568098 | METHOD, LYSIS SOLUTION AND KIT FOR SELECTIVELY DEPLETING ANIMAL NUCLEIC ACIDS IN A SAMPLE | October 2017 | January 2020 | Allow | 27 | 1 | 1 | Yes | No |
| 15567312 | VECTOR-BASED MUTAGENESIS SYSTEM | October 2017 | October 2021 | Allow | 48 | 2 | 1 | Yes | No |
| 15784224 | HUMAN TYPE 55 REPLICATION DEFECTIVE ADENOVIRUS VECTOR, METHOD FOR PREPARING SAME AND USES THEREOF | October 2017 | May 2020 | Allow | 31 | 2 | 1 | Yes | No |
| 15725991 | DE NOVO ENGINEERING OF SITE-SPECIFIC MOLECULES BY TETHERING | October 2017 | March 2020 | Allow | 29 | 1 | 1 | No | No |
| 15720658 | METHODS AND COMPOSITIONS FOR TRANSLATIONAL PROFILING AND MOLECULAR PHENOTYPING | September 2017 | December 2020 | Allow | 39 | 3 | 1 | Yes | No |
| 15561502 | SENSORS FOR DETECTION AND QUANTIFICATION OF MICROBIOLOGICAL PROTEIN SECRETION | September 2017 | October 2021 | Allow | 49 | 2 | 1 | Yes | No |
| 15706353 | SYNTHETIC GENE CLUSTERS | September 2017 | August 2019 | Allow | 23 | 1 | 1 | No | No |
| 15702217 | METHODS AND COMPOSITIONS FOR CLASSIFICATION OF SAMPLES | September 2017 | June 2019 | Allow | 21 | 1 | 0 | No | No |
| 15702126 | Algorithms for Disease Diagnostics | September 2017 | June 2020 | Allow | 33 | 2 | 0 | Yes | No |
| 15329491 | DISCOVERING AND PRODUCING CONDITIONALLY ACTIVE BIOLOGIC PROTEINS IN THE SAME EUKARYOTIC CELL PRODUCTION HOSTS | August 2017 | August 2019 | Allow | 30 | 1 | 1 | No | No |
| 15553552 | PEPTIDES AND USES THEREOF | August 2017 | April 2020 | Allow | 31 | 2 | 1 | Yes | No |
| 15677164 | PROTEIN EXPRESSION STRAINS | August 2017 | May 2018 | Allow | 9 | 1 | 0 | Yes | No |
| 15672789 | COMPOSITIONS AND METHODS RELATING TO GENOMIC MODIFICATIONS IN AVIAN PRIMORDIAL GERM CELLS | August 2017 | October 2019 | Allow | 26 | 1 | 1 | No | No |
| 15664792 | PROTEIN EXPRESSION ENHANCER SEQUENCES AND USE THEREOF | July 2017 | August 2019 | Allow | 24 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MAHATAN, CHANNING S.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MAHATAN, CHANNING S works in Art Unit 1636 and has examined 480 patent applications in our dataset. With an allowance rate of 59.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner MAHATAN, CHANNING S's allowance rate of 59.6% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MAHATAN, CHANNING S receive 2.04 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MAHATAN, CHANNING S is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +48.1% benefit to allowance rate for applications examined by MAHATAN, CHANNING S. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.4% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 58.2% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.5% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.